FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022187773> ?p ?o ?g. }

• W2022187773 endingPage "238" @default.
• W2022187773 startingPage "231" @default.
• W2022187773 abstract "R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. We estimated the point prevalence of Pneumocystis pneumonia in non-Hodgkin lymphoma patients according to the number of R-CHOP cycles and investigated whether cytoreduction by chemotherapy is associated with Pneumocystis pneumonia development. We retrospectively established a cohort of patients who received R-CHOP for non-Hodgkin lymphoma in our institution. Using this cohort, we estimated the incidence rate and point prevalence of definite and probable Pneumocystis pneumonia. To assess factors associated with Pneumocystis pneumonia development several clinical variables, including absolute neutrophil and lymphocyte count at the time of non-Hodgkin lymphoma diagnosis and when the last R-CHOP cycle was administered, were compared between patients with and without Pneumocystis pneumonia. Of 713 patients in the cohort, 14 and 18 patients were diagnosed with definite and probable Pneumocystis pneumonia, respectively. The overall incidence of definite and definite plus probable PCP in NHL patients receiving R-CHOP were 2.0 % (14/713; 95 % CI, 1.1-3.3 %) and 4.5 % (32/713; 95 % CI, 3.2-6.4 %), respectively. This corresponded to 3.8 (95 % CI, 2.2-6.4) and 8.4 (95 % CI, 5.9-11.9) per 1000 persons. Many cases of Pneumocystis pneumonia (22/32, 68.7 %) developed after administration of the fourth R-CHOP cycle. However, there was no statistical difference in Pneumocystis pneumonia prevalence between patients receiving four or more cycles of R-CHOP and fewer than. Higher absolute neutrophil count (4,742/mm(3) vs. 2,627/mm(3); p < 0.01) was associated with Pneumocystis pneumonia development at the last R-CHOP cycle, while absolute lymphocyte count at the time of NHL diagnosis was not. Contrary to expectations, Pneumocystis pneumonia is not a frequent complication of R-CHOP treatment for non-Hodgkin lymphoma. Cytoreduction of R-CHOP might not be a risk factor of Pneumocystis pneumonia development. Universal prophylaxis against Pneumocystis pneumonia during R-CHOP treatment could not be strongly recommended." @default.
• W2022187773 created "2016-06-24" @default.
• W2022187773 creator A5002973930 @default.
• W2022187773 creator A5011578742 @default.
• W2022187773 creator A5022379369 @default.
• W2022187773 creator A5035823234 @default.
• W2022187773 creator A5040109906 @default.
• W2022187773 creator A5044958787 @default.
• W2022187773 creator A5048295115 @default.
• W2022187773 creator A5053591962 @default.
• W2022187773 creator A5067286446 @default.
• W2022187773 creator A5084708203 @default.
• W2022187773 creator A5086479486 @default.
• W2022187773 date "2012-10-10" @default.
• W2022187773 modified "2023-10-16" @default.
• W2022187773 title "Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy" @default.
• W2022187773 cites W1968726483 @default.
• W2022187773 cites W1977813714 @default.
• W2022187773 cites W1989529519 @default.
• W2022187773 cites W2003835506 @default.
• W2022187773 cites W2008003134 @default.
• W2022187773 cites W2022163339 @default.
• W2022187773 cites W2028375716 @default.
• W2022187773 cites W2037853697 @default.
• W2022187773 cites W2041602661 @default.
• W2022187773 cites W2066229119 @default.
• W2022187773 cites W2085296161 @default.
• W2022187773 cites W2095570712 @default.
• W2022187773 cites W2097981315 @default.
• W2022187773 cites W2106928992 @default.
• W2022187773 cites W2107703473 @default.
• W2022187773 cites W2147779566 @default.
• W2022187773 cites W2153470115 @default.
• W2022187773 cites W2160305510 @default.
• W2022187773 cites W2165282359 @default.
• W2022187773 cites W2171370675 @default.
• W2022187773 cites W2172143824 @default.
• W2022187773 cites W2318772898 @default.
• W2022187773 cites W3021917987 @default.
• W2022187773 cites W4321429245 @default.
• W2022187773 doi "https://doi.org/10.1007/s00277-012-1592-1" @default.
• W2022187773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7080131" @default.
• W2022187773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23053189" @default.
• W2022187773 hasPublicationYear "2012" @default.
• W2022187773 type Work @default.
• W2022187773 sameAs 2022187773 @default.
• W2022187773 citedByCount "22" @default.
• W2022187773 countsByYear W20221877732013 @default.
• W2022187773 countsByYear W20221877732014 @default.
• W2022187773 countsByYear W20221877732015 @default.
• W2022187773 countsByYear W20221877732016 @default.
• W2022187773 countsByYear W20221877732017 @default.
• W2022187773 countsByYear W20221877732018 @default.
• W2022187773 countsByYear W20221877732019 @default.
• W2022187773 countsByYear W20221877732020 @default.
• W2022187773 countsByYear W20221877732021 @default.
• W2022187773 countsByYear W20221877732022 @default.
• W2022187773 countsByYear W20221877732023 @default.
• W2022187773 crossrefType "journal-article" @default.
• W2022187773 hasAuthorship W2022187773A5002973930 @default.
• W2022187773 hasAuthorship W2022187773A5011578742 @default.
• W2022187773 hasAuthorship W2022187773A5022379369 @default.
• W2022187773 hasAuthorship W2022187773A5035823234 @default.
• W2022187773 hasAuthorship W2022187773A5040109906 @default.
• W2022187773 hasAuthorship W2022187773A5044958787 @default.
• W2022187773 hasAuthorship W2022187773A5048295115 @default.
• W2022187773 hasAuthorship W2022187773A5053591962 @default.
• W2022187773 hasAuthorship W2022187773A5067286446 @default.
• W2022187773 hasAuthorship W2022187773A5084708203 @default.
• W2022187773 hasAuthorship W2022187773A5086479486 @default.
• W2022187773 hasBestOaLocation W20221877732 @default.
• W2022187773 hasConcept C120665830 @default.
• W2022187773 hasConcept C121332964 @default.
• W2022187773 hasConcept C126322002 @default.
• W2022187773 hasConcept C2776715498 @default.
• W2022187773 hasConcept C2777160144 @default.
• W2022187773 hasConcept C2777559004 @default.
• W2022187773 hasConcept C2777914695 @default.
• W2022187773 hasConcept C2779338263 @default.
• W2022187773 hasConcept C2779725641 @default.
• W2022187773 hasConcept C2780653079 @default.
• W2022187773 hasConcept C61511704 @default.
• W2022187773 hasConcept C71924100 @default.
• W2022187773 hasConcept C90924648 @default.
• W2022187773 hasConceptScore W2022187773C120665830 @default.
• W2022187773 hasConceptScore W2022187773C121332964 @default.
• W2022187773 hasConceptScore W2022187773C126322002 @default.
• W2022187773 hasConceptScore W2022187773C2776715498 @default.
• W2022187773 hasConceptScore W2022187773C2777160144 @default.
• W2022187773 hasConceptScore W2022187773C2777559004 @default.
• W2022187773 hasConceptScore W2022187773C2777914695 @default.
• W2022187773 hasConceptScore W2022187773C2779338263 @default.
• W2022187773 hasConceptScore W2022187773C2779725641 @default.
• W2022187773 hasConceptScore W2022187773C2780653079 @default.
• W2022187773 hasConceptScore W2022187773C61511704 @default.
• W2022187773 hasConceptScore W2022187773C71924100 @default.
• W2022187773 hasConceptScore W2022187773C90924648 @default.
• W2022187773 hasIssue "2" @default.

• next